GSK2983559

GSK2983559 is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 blocks many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples[1].

Product Specifications

UNSPSC

12352005

Target

RIP kinase

Type

Reference compound

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gsk2983559.html

Purity

99.49

Solubility

DMF : < 1 mg/mL (ultrasonic; warming; heat to 80°C) |DMSO : < 1 mg/mL (ultrasonic; warming; heat to 80°C) |Ethanol : < 1 mg/mL (ultrasonic)

Smiles

CC(C)(C)S(C(C(OCCOP(O)([O-])=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O.[H]O[H].[H]O[H].[H]O[H].[Ca+2]

Molecular Formula

C21H23N4O7PS2.1/2Ca.3H2O

Molecular Weight

612.63

References & Citations

[1]Pamela A Haile, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2- ((4- (Benzo[d]thiazol-5-ylamino) -6- (tert-butylsulfonyl) quinazolin-7-yl) oxy) ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 Jul 25;62 (14) :6482-6494.|[2]Shuwei Wu, et al. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors. Bioorg Med Chem Lett. 2022 Sep 2;75:128968.